IMV (IMVIQ) Stock Price, News & Analysis

Company Overview

IMV Inc. is a clinical-stage biotechnology company focused on the development of therapeutic vaccines for oncology and infectious diseases. The company’s core technology, the DPX® immunotherapy platform, is a proprietary lipid‐based delivery system designed to activate T cells and generate durable immune responses against specific disease targets. IMV’s lead oncology candidate, DPX-Survivac, targets the survivin protein, which is commonly overexpressed in solid tumors, and is being evaluated in Phase 2 clinical trials for ovarian and other cancers.

Founded in 1998 and headquartered in Dartmouth, Nova Scotia, IMV has expanded its clinical and translational research footprint across North America and Europe. The company’s pipeline also includes DPX-based vaccine candidates for infectious diseases, leveraging the same platform attributes that support single-dose administration and sustained antigen presentation. By combining preclinical proof of concept with emerging clinical data, IMV aims to demonstrate the broad utility of its technology beyond oncology.

IMV operates through a combination of in-house research and strategic partnerships with academic institutions and industry collaborators. These alliances are intended to accelerate clinical development, optimize combination regimens with established therapies, and explore new indications. As a publicly traded company listed on the Toronto Stock Exchange (TSX: IMV) and the OTCQX market in the United States (OTCMKTS: IMVIQ), IMV continues to advance its pipeline toward potential regulatory filings and commercialization opportunities.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 142 shs
• Average Volume: 3,567 shs
• Market Capitalization: $2 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMVIQ
• CIK: 1734768
• Web: www.imv-inc.com
• Phone: (902) 492-1819
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $330 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.69) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 11,712,000
• Free Float: 11,673,000
• Market Cap: $2 thousand
• Optionable: Not Optionable
• Beta: 0.90